BC Week In Review | Mar 17, 2017
Clinical News

AIR001: Ph I/II started

Mast Therapeutics said the University of Pittsburgh , (Pittsburgh, Pa.) began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for the study. Mast Therapeutics Inc. (NYSE-M:MSTX), San...
BC Week In Review | Mar 15, 2017
Company News

Mast, University of Pittsburgh deal

Mast's Aires Pharmaceuticals Inc. subsidiary and the university partnered to conduct an open-label, dose-escalation, U.S. Phase I/II trial to evaluate the biotech's AIR001 to treat Pseudomonas aeruginosa airway infection in patients with cystic fibrosis (CF)....
BC Week In Review | Dec 30, 2016
Clinical News

AIR001: Ph II INABLE-TRAINING started

Mast began the double-blind, placebo-controlled, U.S. Phase II INABLE-TRAINING trial to evaluate 80 mg inhaled AIR001 thrice daily for 12 weeks in about 68 patients undergoing exercise training as part of standard cardiac rehab. Mast...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Oct 3, 2016
Company News

Mast Therapeutics cardiovascular, hematology news

Mast said it will discontinue clinical development of vepoloxamer ( MST-188 ) and focus on developing aironite ( AIR001 ) to treat heart failure with preserved ejection fraction (HFpEF). Last month, Mast reported that vepoloxamer missed the primary endpoint...
BC Week In Review | Aug 8, 2016
Clinical News

Aironite: Phase II started

Mast said Duke Clinical Research Institute began the double-blind, placebo-controlled, crossover, U.S. Phase II INDIE-HFpEF trial to evaluate thrice-daily AIR001 in about 100 heart failure patients ages >40 with preserved ejection fraction. Mast Therapeutics Inc....
BC Week In Review | Feb 8, 2016
Clinical News

Aironite: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 30 heart failure patients with preserved ejection fraction showed that 90 mg inhaled AIR001 met the primary endpoint of improving pulmonary capillary wedge pressure at...
BC Week In Review | Mar 2, 2015
Clinical News

Aironite: Phase IIa amended

Mast said the University of Pittsburgh amended an open-label, U.S. Phase IIa trial of 45 and 90 mg inhaled AIR001 to include 20 patients with WHO group II pulmonary hypertension (PH) and PH associated with...
BC Week In Review | Mar 2, 2015
Clinical News

Aironite: Phase IIa started

Mast said the Mayo Clinic began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 90 mg inhaled AIR001 in about 30 patients. Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif.   Product: Aironite ( AIR001 )  ...
BC Week In Review | Sep 15, 2014
Clinical News

Aironite: Phase II data

Top-line data from the open-label, international Phase II AIR001-CS05 trial in 29 patients with PAH showed that all doses of AIR001 improved median PVR, the primary endpoint, and 6MWD, a secondary endpoint. Patients received 46...
Items per page:
1 - 10 of 16